No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RNA240719C50000
- 0.60
- 0.000.00%
15min DelayTrading Jun 17 14:54 ET
0.00High0.00Low
0.00Open0.60Pre Close0 Volume5 Open Interest50.00Strike Price0.00Turnover138.78%IV10.34%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.60Extrinsic Value100Contract SizeAmericanOptions Type0.2169Delta0.0575Gamma76.43Leverage Ratio-0.3211Theta0.0006Rho16.58Eff Leverage0.0108Vega
Intraday
- 5D
- Daily
News
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances.T
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $56
TD Cowen analyst Ritu Baral maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $56.According to TipRanks data, the analyst has a success rate of 45.0% and a total
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
Have Insiders Sold Avidity Biosciences Shares Recently?
We'd be surprised if Avidity Biosciences, Inc. (NASDAQ:RNA) shareholders haven't noticed that the Chief Human Resources Officer, Teresa McCarthy, recently sold US$386k worth of stock at US$39.13 per s
Avidity Biosciences(RNA.US) Director Sells US$187.95K in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of common stock on Jun 20, 2024 at an average price of $37.5901 for a total value of $187.95K.Source: Announcement What is state
Comments
The FOMC left rates the same Wednesday afternoon, pointing to about one cut this year. The market was genuinely higher with record index prices.
As a recap just past 10:20 AM EST, the $S&P 500 Index(.SPX.US$ was climbing past a record by 1.23%, the $Dow Jones Industrial Average(.DJI.US$ climbed 0.57%, and the $Nasdaq Composite Index(.IXIC.US$ climbed 1.43%. The indexes gapped higher Wednesday morning, the dow jumping 500...
As a recap just past 10:20 AM EST, the $S&P 500 Index(.SPX.US$ was climbing past a record by 1.23%, the $Dow Jones Industrial Average(.DJI.US$ climbed 0.57%, and the $Nasdaq Composite Index(.IXIC.US$ climbed 1.43%. The indexes gapped higher Wednesday morning, the dow jumping 500...
22
2
$Avidity Biosciences(RNA.US$ Avidity Bioscience Announces Proposed Public Offering Of $300M Of Common Stock
1
Morning mooers! It is Wednesday, June 12th: FOMC rate decision day! The market was lower overall Tuesday but hit all time highs in the S&P 500 and Nasdaq right before the close on Apple AI gains. Today the market is even higher, with most quities climbing.
My name is Kevin Travers, here are stories from the herd on Wall Street today.
$Oracle (ORCL.US)$ climbed 12%, the highest on the S&P 500, after the firm's earnings came ...
My name is Kevin Travers, here are stories from the herd on Wall Street today.
$Oracle (ORCL.US)$ climbed 12%, the highest on the S&P 500, after the firm's earnings came ...
29
$Avidity Biosciences(RNA.US$
IF YOU LOSS THEN REVERSE NOW ( 5X - 15X - 25X ) & TRADE > $100 PRICE ONLY 😊😊😊🌟🌟🌟😍😍😍👍👍👍
IF YOU LOSS THEN REVERSE NOW ( 5X - 15X - 25X ) & TRADE > $100 PRICE ONLY 😊😊😊🌟🌟🌟😍😍😍👍👍👍
$Avidity Biosciences(RNA.US$ Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) For Myotonic Dystrophy Type 1
Benzinga· 3 mins ago
Benzinga· 3 mins ago
Read more
NVDAvsTSLA : Just one small interest rate cut made everyone happy
Sigma-Jobs : OK, very good